Lifeward Ltd. · NASDAQ:LFWD
Lifeward — ReWalk Robotics — Investor Presentation (April 2023)
31 slides from Lifeward's investor presentation, Apr 28, 2023
Slide 1: ReWalk Robotics Investor Presentation April 2023
ReWalk Robotics Investor Presentation April 2023 Confidential – ReWalk Robotics 2023 NASDAQ:RWLK
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, Section 27A of the U.S. Securities Act of 1933, and Section 21E of the U.S. Securities Exchange Act of 1934. All statements contained in t
Slide 3: Advancing Quality of Life After Neurological Injury or Disability
Advancing Quality of Life After Neurological Injury or Disability Confidential – ReWalk Robotics 2023 ReWalk Robotics Mission: To fundamentally improve the quality of life for individuals with neurological injury or disability through innovative technologies that enable mobility and wellness in reha
Slide 4: Getting People Back to Doing What They Love
Neurologic disease or injury, including spinal cord injury (“SCI”) or stroke, historically results in a lifetime of disability and chronic health complications from a sedentary lifestyle. ReWalk Robotics provides solutions that leverage robotics and biomechanics to facilitate neurorehabilitation in
Slide 5: A Leader in NeuroRehabilitation Solutions
Strategic catalysts in 2023 FDA approval of stairs / curb capability CMS approval for Medicare reimbursement of exoskeletons FDA approval of next-generation of exoskeleton Consolidation activity through strategic acquisitions Market-leading innovation – First-to-market personal exoskeleton for spina
Slide 6: A History of Innovation
A History of Innovation Confidential – ReWalk Robotics 2023 ReWalk Robotics has consistently pioneered NeuroRehabilitation solutions as standard of care 2014 2015 2019 2020 2021 2022 2023 …establish exoskeleton SOP with the Dept. of Veterans Affairs …establish HCPCS code for exoskeletons with Medica
Slide 7: NeuroRehabilitation Market is Sizeable and Growing
NeuroRehabilitation Market is Sizeable and Growing Confidential – ReWalk Robotics 2023 NeuroRehabilitation Equipment Market1 $ in billions CAGR of 8.3% NeuroRehabilitation Equipment Market by Product Type1 Neurorehabilitation: The rehabilitation and management of patients with diseases, injury, or d
Slide 8: NeuroRehabilitation: Growing Market Opportunities
NeuroRehabilitation: Growing Market Opportunities Confidential – ReWalk Robotics 2023 Market tailwinds that ReWalk will leverage: Technological advances. Continued innovation and efficiency improvements in robotics, sensors, power systems Market adoption. Introduction of VR & app-based patient servi
Slide 9: Product Portfolio
Product Portfolio Confidential – ReWalk Robotics 2023 9
Slide 10: A Growing Portfolio of Solutions for NeuroRehabilitation
A Growing Portfolio of Solutions for NeuroRehabilitation Confidential – ReWalk Robotics 2023 ReWalk Personal Exoskeleton Cutting edge technology that provides paralyzed individuals with access to greater mobility and the health-related benefits of walking in daily life. ReStore Exo-Suit Versatile, r
Slide 11: Flagship Product – ReWalk Personal Exoskeleton
Flagship Product – ReWalk Personal Exoskeleton Confidential – ReWalk Robotics 2023 The ReWalk Personal Exoskeleton enables paralyzed individuals with spinal cord injury to stand, walk, and ascend or descend stairs and curbs during everyday activities. The most widely available and utilized personal
Slide 12: The Leader in Exoskeleton Technology
The Leader in Exoskeleton Technology Confidential – ReWalk Robotics 2023 Unprecedented freedom – Only personal exoskeleton enabling ambulatory access to real-world environments, including locations with stairs or curbs Natural gait – Only personal exoskeleton with six adjustable degrees of freedom f
Slide 13: Proven Health Benefits
Regular access to exoskeleton-assisted walking results in a multitude of health and wellness benefits for people with spinal cord injury2-8 Frequently reported benefits in literature include reductions in common comorbidities after SCI, including: Reduced spasticity Improved bowel/bladder function R
Slide 14: Increasing Progress of Reimbursement/Coverage
Confidential – ReWalk Robotics 2023 Germany 65M lives covered by DGUV (workers compensation) in Germany since 2019 Contractual coverage for 30% of all Germans through Statutory and Private health insurance plans 23.2M lives covered since 2020 Additional 2M covered lives added in 2021 US 9M US Vetera
Slide 15: SCI Market Potential – Driven by CMS Coverage
SCI Market Potential – Driven by CMS Coverage Confidential – ReWalk Robotics 2023 Eligible Candidates11,12 Reimbursement Pathway13,14 Potential Total Addressable Market Prevalence of SCI Survivors US 296,0009 Germany 74,00010 Global 7.1 Million10 US 15,416 Germany 2,064 Global 17,480 Potential TAM $
Slide 16: Secondary Product Line – ReStore Soft Exo-Suit for Stroke
Unique capabilities – only FDA and CE-cleared tool offering on-demand mechanical assistance to retrain post-stroke walking function during “push-off” (propulsion) Enhanced gait training – improves training specificity and intensity by promoting power and symmetry in forward propulsion, as well as ef
Slide 17: Stroke Market Potential
Stroke Market Potential Confidential – ReWalk Robotics 2023 Personal Sales (Future State) Stroke Rehabilitation Centers20 Direct Sales Presence In-Clinic Sales (Current State) Inpatient Facilities Outpatient Clinics US 115217 44,00018 Germany 28819 11,00019 Global 27,80019 1M19 Incidence Prevalence
Slide 18: Stroke Market Potential
Stroke Market Potential Confidential – ReWalk Robotics 2023 Personal Sales (Future State) Stroke Rehabilitation Centers20 Clinic Market 1,824 Personal Market 5.8M Direct Sales Presence In-Clinic Sales (Current State) Inpatient Facilities Outpatient Clinics US 115217 44,00018 Germany 28819 11,00019 G
Slide 19: Distributed Product Line – MyoCycle FES
Broad indications – widely applicable across the NeuroRehabilitation spectrum, with specialized models for in-clinic and at-home use Easy to use – simple setup, with intuitive controls allowing home users and clinicians to rapidly achieve therapeutic goals Proven – FDA cleared to prevent muscle atro
Slide 20: MyoCycle FES Market Potential
MyoCycle FES Market Potential Confidential – ReWalk Robotics 2023 SCI Stroke MS US 296,00024 7M25 1.0M26 Personal (Home Use) Sales Medical Eligibility27 US Clinic Market 3,600 US Personal Market 67,000 Total 70,600 Potential Total Addressable Market NeuroRehab Focused Clinics31 ReWalk Dist. Rights28
Slide 21: Consolidation Strategy
Consolidation Strategy Confidential – ReWalk Robotics 2023 21
Slide 22: Consolidation Will Add Scale and Supplement Growth
Enhancements to technology and features of ReWalk Exoskeleton Expansion of access through greater reimbursement coverage Internal development of new products Increasing penetration for distributed products Consolidation Will Add Scale and Supplement Growth Confidential – ReWalk Robotics 2023 Approve
Slide 23: NeuroRehabilitation Market Attractive for Consolidation
Distribution of NeuroRehabilitation Technology Providers NeuroRehabilitation Market Attractive for Consolidation Confidential – ReWalk Robotics 2023 Fragmented industry with many small players Mostly private companies with limited access to capital Innovative technologies with distribution constrain
Slide 24: Acquisition Program Designed to Accelerate Path to Profitability
Leverage Key Capabilities Acquisition Program Designed to Accelerate Path to Profitability Confidential – ReWalk Robotics 2023 Field Sales & Marketing Clinical R&D Regulatory / Quality Reimbursement Operations / Integration Public company resources Opportunity for ReWalk Robotics to Leverage Its Pos
Slide 25: Deep and Talented Leadership Team
Deep and Talented Leadership Team Larry JasinskiChief Executive Officer Mike LawlessChief Financial Officer Jeannine LynchVice President, Strategy & Market Access Kathleen O'DonnellVice President, Marketing & New Business Development Miri ParienteVice President, Operations, Regulatory & Quality Davi
Slide 26: Financial Summary
Financial Summary Confidential – ReWalk Robotics 2023 $67.9 M Cash & Cash Equivalents (as of Dec. 31, 2022) Cash No Debt Debt Expected cash into 2025+, depending on acquisitions Cash Runway Well Positioned for Funding Internal Growth and Consolidation Strategy
Slide 27: 2023 Milestones & Catalysts
2023 Milestones & Catalysts Confidential – ReWalk Robotics 2023 FDA clearance for use of our ReWalk Personal exoskeletons on stairs and curbs extends competitive advantage Exoskeleton reimbursement coverage by Medicare with claims processed and paid by MACs 510k submission for FDA clearance of the
Slide 28: Well Positioned for Future Growth
Expanding addressable market in United States and Germany; first Medicare claims ongoing ReWalk Robotics Well Positioned for Future Growth Large, growing and fragmented NeuroRehabilitation market with many attractive candidates for consolidation Fundamentally changes lives for individuals with spina
Slide 29: Thank you!
NASDAQ:RWLK Thank you! Confidential – ReWalk Robotics 2023
Slide 30: Footnotes and references
1 Allied Health Neurorehabilitation Market Report: https://www.alliedmarketresearch.com/neurorehabilitation-market-A10461 2 Asselin et al., Arch Phys Med Rehab (2021) 3 Gorman et al., J Clin Med (2021) 4 Duddy et al., Sensors (2021) 5 Shackleton et al., J Rehab Med (2019) Juszczak et al., Topics Spi
Slide 31: Footnotes and references
15 www.nichd.nih.gov/health/topics/stroke/conditioninfo/risk 16 www.strokeinfo.org/stroke-facts-statistics/ 17 www.medpac.gov/wp-content/uploads/2021/10/mar21_medpac_report_ch9_sec.pdf 18 www.ibisworld.com/industry-statistics/number-of-businesses/physical-therapy-rehabilitation-centers-united-states